Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Defence Therapeutics Inc. Stock

Price
Target price
€0.35

€0.35

20.830%
0.06
20.830%
-
 
13:15 / Tradegate WKN: A3CN14 / Name: Defence Therapeutics Inc. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Defence Therapeutics Inc. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Defence Therapeutics Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Defence Therapeutics Inc.

sharewise wants to provide you with the best news and tools for Defence Therapeutics Inc., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive OfficerPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer

Montreal, QC, Canada, August 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing

irwpresse_en 
0 04.08.26
Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
DefenceTherapeutics_17-08-2026_ENPRcom

Montreal, QC, Canada, August 17, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded

irwpresse_en 
0 09:18
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical PlatformPhoto, wide shot, wide-angle lens, Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform

Montreal, QC, Canada, July 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing

irwpresse_en 
0 08.07.26
Defence Therapeutics to Participate in BIO International Convention 2026 Next Week for Strategic Partnership DiscussionsPhoto, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png
Defence Therapeutics to Participate in BIO International Convention 2026 Next Week for Strategic Partnership Discussions

Montreal, QC, Canada, June 17th, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular

irwpresse_en 
0 17.06.26
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to its Board of DirectorsPhoto, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to its Board of Directors

Montreal, QC, Canada, June 3rd, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular

irwpresse_en 
0 03.06.26
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to its Board of DirectorsPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to its Board of Directors

Montreal, QC, Canada, June 1st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular

irwpresse_en 
0 01.06.26
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing CapabilitiesPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities

Montreal, QC, Canada, May 19th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular

irwpresse_en 
0 19.05.26
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000 Photo, wide shot, wide-angle lens, Mental health care service, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ce3b930-5e2a-4215-b686-0ad0eb0b922a.png
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

Montreal, QC, Canada, March 9, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular

irwpresse_en 
0 09.03.26
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in MarchPhoto, wide shot, wide-angle lens, Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Montreal, QC, Canada, March 2nd, 2026 -- Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its

irwpresse_en 
0 02.03.26